Research and Markets (http://www.researchandmarkets.com/research/446d65/indonesia_pharmace) has announced the addition of the "Indonesia Pharmaceuticals and Healthcare Report Q4 2009" report to their offering.
This Indonesia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Indonesia's pharmaceuticals and healthcare industry.
In this Business Environment Rating matrix for Q409, Indonesia once again occupies 12th position, out of the 15 regional markets surveyed in the Asia Pacific region. The country's pharmaceutical rating is lower than in the previous quarter, with most other markets being downgraded due to the current economic challenges. Main drawbacks to investment in Indonesia include political instability, corruption, low per-capita spending on pharmaceuticals - which is further hampered by rising costs of drugs - and a small proportion of elderly people in the country. On the other hand, annual growth of its pharmaceutical market, coupled with rising population numbers and a relatively promising economic base, will continue to attract multinationals willing to expose themselves to a risky operating environment.
By 2013, the market should reach a value of IDR39,749bn (US$4.60bn), up from IDR26,393bn (US$2.79bn) in 2008. The figures represent a compound annual growth rate (CAGR) of 8.53% in local currency terms, although the forecasts are at risk from economic and regulatory factors. Given the lack of a reimbursement scheme, local population will continue to rely on cheaper, mostly domestically-produced generics. Consequently, copy drugs' total market share is expected to increase from 21.7% in 2008 to 25.5% in 2013, at the expense of their patented counterparts. This situation will be compounded by the possible closure of some multinational sale offices currently operating in Indonesia, due to the requirement that foreign companies either invest locally or leave.